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Background: We performed this study to determine the dose-response of hemoglo-
bin raffimer administered in conjunction with intraoperative autologous donation in
patients undergoing coronary artery bypass grafting surgery. A secondary objective
was to evaluate hemoglobin raffimer for reducing the incidence of allogeneic red
blood cell transfusions.
Methods: This was a phase II, single-blind, multicenter, placebo-controlled, open-
label study. Patients undergoing coronary artery bypass grafting with cardiopulmo-
nary bypass and intraoperative autologous donation were randomized to receive a
single dose of hemoglobin raffimer or control (10% pentastarch). Patients were
sequentially enrolled in a dose block of 250, 500, 750, and 1000 mL.
Results: Sixty patients received hemoglobin raffimer (n  30) or control (n  30).
Hemoglobin raffimer was well tolerated. Most (98%) adverse events were mild or
moderate in severity. There was an expected dose-dependent increase in the inci-
dence of blood pressure increases and jaundice in hemoglobin raffimer–treated
patients. In a dose-pooled analysis of hemoglobin raffimer versus control, increased
blood pressure (43% vs 17%), nausea (37% vs 33%), and atrial fibrillation (37% vs
17%) were the most frequently reported adverse events. All serious adverse events
were considered unrelated or unlikely to be related to study drug. No hemoglobin
raffimer–treated patient required an intraoperative allogeneic red blood cell trans-
fusion, compared with 5 (17%) pentastarch-treated patients (P  .052). This
advantage of hemoglobin raffimer was maintained at 24 hours after surgery (7% vs
37%; P  .010) and up to 5 days after surgery (10% vs 47%; P  .0034).
Conclusions: Hemoglobin raffimer was not associated with any serious adverse
events in patients undergoing primary coronary artery bypass grafting with cardio-
pulmonary bypass and intraoperative autologous donation in a dose-response study
up to 1000 mL. Hemoglobin raffimer was effective in facilitating decreased expo-
sure or avoidance of allogeneic red blood cell transfusions when used in conjunction
with intraoperative autologous donation.
Although blood transfusion is now a generally safe procedure, casesof ABO incompatibility, bacterial contamination, and viral con-tamination are still reported and can be life threatening.1,2 Bleed-ing after coronary artery bypass grafting (CABG) can be a majorsurgical complication, and excessive bleeding contributes to post-operative morbidity and mortality and the need for transfusion.3,4
In the United States, an estimated 20% of allogeneic blood transfusions occur in
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cardiac surgical patients.5 Continued concern over the
safety of red blood cell (RBC) transfusions has fostered
alternative strategies for treating bleeding in patients having
CABG surgery,6 such as blood conservation by intraopera-
tive autologous donation (IAD) to reduce patient need for
banked blood. This technique involves the removal of sev-
eral units of a patient’s blood immediately before operation.
This collected blood is held on reserve in the operating
room for retransfusion when the patient reaches a specified
transfusion trigger. In the IAD procedure, the harvested
blood volume is replaced with a plasma expander or an
oxygen carrier. Several oxygen carriers, members of a new
pharmacologic class called hemoglobin-based oxygen car-
riers, are in clinical development.
Hemoglobin raffimer, an oxidized raffinose cross-linked
human hemoglobin (Hemolink; Hemosol Inc, Toronto, On-
tario, Canada), is a highly purified hemoglobin-based oxy-
gen carrier prepared from human RBCs. The manufacturing
process and product specifications for hemoglobin raffimer
have previously been described.7 The cross-linking of the
hemoglobin moiety results in a stabilized hemoglobin mol-
ecule with an increased plasma half-life and improves ox-
ygen offloading by decreasing the hemoglobin component’s
affinity for oxygen.8 Hemoglobin raffimer has been evalu-
ated in healthy volunteers to determine the tolerability,
pharmacokinetics, and pharmacodynamics of increasing
doses.9 Hemoglobin raffimer is distributed mainly in the
plasma, with peak concentrations consistent with a volume
of distribution equal to the plasma volume. Similar to en-
dogenous hemoglobin, hemoglobin raffimer seems to be
catabolized via the heme oxygenase pathway, resulting in
transient increases in serum bilirubin levels that are propor-
tional to the hemoglobin raffimer dose.9 As a result of the
acceptable tolerance and pharmacokinetic profile in healthy
volunteers, hemoglobin raffimer was further assessed in a
phase II study.
The objective of this phase II trial was to evaluate the
effects and efficacy of escalating doses of hemoglobin raf-
fimer administered in conjunction with IAD on tissue oxy-
genation and on reducing the incidence and volume of
allogeneic RBC transfusions in patients undergoing CABG
surgery.
Methods
Patient Eligibility
Men and women from 18 to 80 years of age who were scheduled
for primary elective CABG surgery with cardiopulmonary bypass
(CPB) were eligible for inclusion in the study. Eligible patients had
a hematocrit level that would allow harvesting of 500 to 1500 mL
of intraoperative autologous blood to reach an on-CPB target
hematocrit level of 0.20 to 0.24. Exclusion criteria included a
history of cardiac surgery, myocardial infarction (MI) within 4
weeks before the scheduled operation, congestive heart failure, left
ventricular ejection fraction of less than 30%, and clinically sig-
nificant renal, liver, or pancreatic disease. The study was con-
ducted in accordance with the Declaration of Helsinki (Republic of
South Africa, Oct 1996) and was approved by the institutional
review boards of the participating study centers. All patients pro-
vided written, informed consent.
Study Design and Treatment
This randomized, single-blind, controlled, open-label study was
conducted at multiple sites in Canada (6 sites) and in the United
Kingdom (1 site). All patients underwent operation via a median
sternotomy with saphenous veins, internal thoracic arteries, or
both, as conduits according to each institution’s standard proce-
dure. Patients were screened before operation and were random-
ized in a 1:1 ratio to receive hemoglobin raffimer or 10% pen-
tastarch (Pentaspan), which served as the control. Four dose blocks
were established that consisted of escalating volumes (250, 500,
750, and 1000 mL) of hemoglobin raffimer and pentastarch. The
doses were chosen on the basis of the volumes estimated to be used
clinically. Patients were sequentially enrolled starting with the
lowest-volume dose block, and dose block enrollment was com-
pleted in respective order. Autologous blood was harvested after
heparinization and immediately before initiation of CPB. A single
dose of hemoglobin raffimer or pentastarch was administered as a
1:1 volume replacement by addition into the bypass pump reser-
voir at initiation of CPB. The volume of autologous blood to be
collected was calculated by using the formula
Volume [(70 mL/kg) (weight) (Hb 7 g/dL)]
 [(7 g/dL) (prime  750 mL)]  Hb,
where volume is the volume in milliliters of autologous blood to be
collected, weight is the patient’s body weight in kilograms, hemo-
globin is measured hemoglobin in grams per deciliter, and prime is
the estimated pump prime volume in milliliters.
All autologous blood donated at the beginning of the bypass
procedure was returned to the patient either when a protocol-
defined transfusion trigger was reached during the operation or at
the completion of the surgical procedure, regardless of the hemo-
globin level.
Crystalloid solution was infused as required for additional
volume management. Transfusions were administered on the basis
of specific transfusion triggers, as defined by the consensus of a
core group of investigators, and represent their standards of clin-
ical practice. A transfusion trigger was defined as hemoglobin less
than 6.0 g/dL or less than 65% oxygen saturation of mixed venous
blood during CPB and as hemoglobin less than 7.0 g/dL or less
than 65% oxygen saturation of mixed venous blood after CPB. In
the intensive care unit (ICU), after the removal of the pulmonary
artery catheter, the transfusion trigger was hemoglobin less than
7.5 g/dL or hematocrit less than 0.24; on the ward, it was hemo-
globin less than 8.0 g/dL or hematocrit less than 0.27.
Adverse Events and Efficacy Measurements
Patients were monitored in the hospital (typically 4 to 7 days) and
assessed at a follow-up visit 5 to 8 weeks after discharge. Assess-
ments were performed during the patient’s hospital stay and at the
follow-up visit and included adverse events, laboratory measure-
ments (including clinical chemistry, cardiac enzymes, hematology,
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urinalysis, and anti-hemoblobin raffimer antibody), blood gases,
fluid input and output, mediastinal chest-drain volumes, electro-
cardiograms (ECGs), vital signs, and physical examinations. The
presence of hemoglobin raffimer may interfere with some clinical
laboratory tests because of the characteristic absorption pattern of
hemoglobin. Interference testing was performed at the central
laboratory and at all local laboratories that analyzed patient sam-
ples from this study. Correction factors were applied at each
laboratory and for each analyte as appropriate. A blinded, inde-
pendent cardiologist and the Safety Monitoring Committee
(blinded) assessed the ECG and myocardial muscle creatine kinase
isoenzyme (CK-MB) data for all patients after each dose block.
The diagnosis of MI was based on a combination of ECG changes
and myocardial enzyme increases. A definitive MI was defined as
a new Q wave, new left bundle branch block, or new pathologic R
waves in combination with a CK-MB greater than 40 ng/mL at 12
hours after crossclamp removal. A probable MI was defined as a
new ischemic ECG abnormality or loss of R wave in combination
with a CK-MB clamp 40 ng/mL at 12 hours after crossclamp
removal. Enzyme increases alone were not considered diagnostic
of an MI.
Serum samples were screened for antibodies by using a solid-
phase, enzyme-linked immunosorbent assay to measure the pres-
ence of anti-hemoglobin raffimer immunoglobulin G and immu-
noglobulin M reactivity before and after infusion of hemoglobin
raffimer or pentastarch. Results were determined to be negative if
they were less than the mean plus 3 SD of the results from an
untreated population (data not shown). Positive screening results
were confirmed by adsorption on hemoglobin raffimer–coated
Sepharose 4B and retesting by the enzyme-linked immunosorbent
assay method.
Efficacy assessments included systemic oxygenation measure-
ments (oxygen saturation in arterial and venous blood, lactate, base
excess, oxygen delivery and consumption, and oxygen extraction
coefficient or ratio). Arterial and mixed venous blood gas mea-
surements were performed at 15-minute intervals during operation
and then at 1, 6, and 24 hours after surgery as long as pulmonary
artery and radial arterial catheters were in place. The incidence of
intraoperative autologous transfusions and the incidence and vol-
ume of perioperative allogeneic blood transfusions were also de-
termined.
Statistical Methods
Data were converted to SAS (SAS Institute, Cary, NC) data sets by
using SAS System, release 6.12. The frequencies of treatment-
emergent adverse events were coded with the COSTART system
(Coding Symbols for a Thesaurus of Adverse Reaction Terms;
US Food and Drug Administration, 1993). Summary statistics
were calculated for demographic and laboratory values. All
treated patients were included in the primary and secondary out-
come analyses. Descriptive statistics, including mean, n, SD, and
SEM, were calculated for all numeric efficacy variables. Data
on systemic oxygenation parameters were analyzed with the re-
peated-measures analysis of variance method. A 2 test was used
to detect the difference in frequency distribution of allogeneic
transfusions.
Results
Patient Demographics
A total of 79 patients were enrolled in the study. Of these
patients, 13 were eliminated by the screening process, and 6
were randomization failures (patients who passed the initial
screening process and were randomized to a treatment
group but were discontinued from the study before receiv-
ing study medication). Sixty patients received study treat-
ment (hemoglobin raffimer or pentastarch), and 53 patients
completed the study. Seven patients did not complete the
study—3 voluntarily withdrew from the study, and 4 did not
attend the follow-up visit. Five of the 7 patients who dis-
continued were in the hemoglobin raffimer groups (1 each
from the 250-, 500-, and 1000-mL dose blocks and 2 from
the 750-mL dose block). Patient demographics are summa-
rized in Table 1. No significant differences were observed
among the treatment groups for any demographic parame-
ter. IAD harvest volume (mean  SD) was comparable in
TABLE 1. Patient demographics
Characteristic
Hb raffimer (mL) (n  30) Pentastarch (mL) (n  30)
250 500 750 1000 250 500 750 1000
Sex (n)
Male 4 5 8 9 4 3 8 7
Female 1 0 2 1 1 2 2 3
Age (y)
Mean 68 57 60 58 58 66 61 64
Range 63–73 47–69 42–71 47–74 43–68 61–70 38–75 48–74
Weight (kg)
Mean 84 77 83 84 78 79 79 81
Range 76–89 65–85 68–93 66–117 68–89 72–88 64–100 54–99
Race
Caucasian 5 4 9 10 3 5 9 8
Other 0 1 1 0 2 0 1 2
Hb, Hemoglobin.
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both study groups, with 1100  345 mL collected in the
hemoglobin raffimer patients and 952  269 mL in the
control patients.
Efficacy Outcomes
All randomized patients who received study treatment were
included in the efficacy analysis. The incidence of IAD
transfusions (Figure 1 and Table 2) was significantly (P 
.0021) lower in hemoglobin raffimer–treated patients com-
pared with pentastarch-treated patients (7% vs 43%). Fur-
thermore, no patient treated with hemoglobin raffimer re-
quired an intraoperative transfusion of allogeneic RBCs,
whereas 5 (17%) pentastarch-treated patients required a
transfusion (P  .052). Significantly fewer hemoglobin
raffimer–treated patients required an RBC transfusion com-
pared with pentastarch-treated patients up to 24 hours after
surgery (7% vs 37%; P  .010) and up to 5 days after
surgery (10% vs 47%; P  .0034). The overall mean time
to the first transfusion trigger was longer in the hemoglobin
raffimer group compared with the pentastarch group by
approximately 5 hours.
Among patients who received RBC transfusions over the
study duration, the 3 hemoglobin raffimer–treated patients
received a smaller average volume (ie, fewer units) than the
14 pentastarch-treated patients (367 29 mL vs 890  818
mL). However, this difference was not statistically signifi-
cant.
There was also an expected increase in whole blood total
hemoglobin in hemoglobin raffimer–treated patients com-
pared with pentastarch-treated patients. In addition, serum
hemoglobin levels increased rapidly after hemoglobin raf-
fimer infusion and were dose dependent. Mean peak serum
hemoglobin levels (5.8, 9.8, 15.5, and 17.8 g/dL for the
250-, 500-, 750-, and 1000-mL dose blocks, respectively)
were observed in serum samples analyzed within 1 hour
after operation. Mean serum hemoglobin levels returned to
predose levels by 24 hours in the 250-mL dose block and by
48 hours in the 500- and 750-mL dose blocks, respectively.
The mean serum hemoglobin level remained slightly in-
creased in the 1000-mL hemoglobin raffimer group at 48
hours after surgery but returned to baseline by postoperative
day 5. The mean hematocrit values at postoperative day 5
(or discharge) were 0.29  0.03 for patients treated with
hemoglobin raffimer and 0.30  0.04 for patients treated
with pentastarch.
Adverse Events
Hemoglobin raffimer was not associated with any serious
adverse events in an escalating dose up to 1000 mL. Blood
gas measurements were stable and comparable across all
treatment groups, as were fluid input and output measures
and mediastinal chest-drain volumes. Adverse events re-
ported by treatment group in each dose block are shown in
Table 3. Most (98%) adverse events were mild or moderate
in severity and were transient. There were expected dose-
dependent increases in the incidence of transient increases
in blood pressure and jaundice in hemoglobin raffimer–
treated patients. After adverse events were analyzed by
study drug dose, the data were pooled for the 4 dose blocks
of hemoglobin raffimer and pentastarch. The most fre-
quently reported adverse events reported in this pooled
analysis are summarized in Table 4. Blood pressure in-
Figure 1. Percentage of patients undergoing coronary artery bypass grafting with cardiopulmonary bypass who
required a transfusion. Hb, Hemoglobin; IAD, intraoperative autologous donation; RBC, red blood cell; POD,
postoperative day.
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creases, nausea, atrial fibrillation, and jaundice were among
the events reported more frequently with hemoglobin raf-
fimer treatment than with pentastarch treatment.
There were 4 reports of severe adverse events in the
hemoglobin raffimer–treated group and 3 in the pentastarch-
treated group. One severe adverse event (arterial hyperten-
sion) was reported in the 500-mL hemoglobin raffimer
group. Congestive heart failure/malaise, increased amylase,
and supraventricular tachycardia were reported in the
1000-mL hemoglobin raffimer group. A sternal wound in-
fection and stroke were reported as severe adverse events in
the 250-mL pentastarch group, and ventricular fibrillation
was reported in the 750-mL pentastarch group. In addition,
6 hemoglobin raffimer–treated and 9 pentastarch-treated
patients experienced a total of 17 serious adverse events,
which required longer hospitalization. All 17 of these seri-
ous events were considered by the investigator to be unre-
lated or unlikely to be related to the study drug. No deaths
occurred during the study.
Increased blood pressure occurred more often in hemo-
globin raffimer–treated patients (13 of 30; 43%) than in
pentastarch-treated patients (5 of 30; 17%). Most blood
pressure increases in hemoglobin raffimer–treated patients
occurred in the ICU, returned to baseline levels within 24
hours, and were mild to moderate in magnitude, ranging
from 1% to 4% in the 750-mL dose blocks and 14% to 25%
in the 500-mL dose blocks. Only 4 hemoglobin raffimer–
treated patients and 1 pentastarch-treated patient experi-
enced a 25% or more increase in mean arterial pressure.
According to the investigators’ assessment, 6 patients in the
hemoglobin raffimer group and 8 patients in the pentastarch
group had MIs reported as adverse events.
Biochemical Outcomes
There were no unexpected differences in clinical laboratory
measurements in the hemoglobin raffimer and control
groups, with the exception of serum lipase, which was
increased in 7 (23%) hemoglobin raffimer–treated patients.
TABLE 2. Incidence of transfusions by treatment dose
Variable
Hb raffimer (mL) Pentastarch (mL)
250
(n  5)
500
(n  5)
750
(n  10)
1000
(n  10)
250
(n  5)
500
(n  5)
750
(n  10)
1000
(n  10)
IAD transfusion 1 0 1 0 2 1 5 5
Allogeneic RBC transfusion
Intraoperative 0 0 0 0 1 1 2 1
POD 1 0 1 0 1 1 2 3 5
POD 5 0 1 1 1 2 3 4 5
Hb, Hemoglobin; IAD, intraoperative autologous donation; RBC, red blood cell; POD, postoperative day.
Data are number of patients.
TABLE 3. Adverse events reported by treatment group
Adverse event
Hb raffimer (mL) Pentastarch (mL)
250
(n  5)
500
(n  5)
750
(n  10)
1000
(n  10)
250
(n  5)
500
(n  5)
750
(n  10)
1000
(n  10)
Hypertension 0 2 (40) 6 (60) 5 (50) 0 2 (40) 3 (30) 0
Nausea 0 2 (40) 6 (60) 3 (30) 1 (20) 1 (20) 3 (30) 6 (60)
Atrial fibrillation 2 (40) 2 (40) 2 (20) 5 (50) 1 (20) 2 (40) 0 2 (20)
Jaundice 0 1 (20) 4 (40) 8 (80) 0 0 0 0
Myocardial infarction 2 (40) 1 (20) 0 3 (30) 4 (80) 1 (20) 1 (10) 2 (20)
Fever 1 (20) 1 (20) 2 (20) 2 (20) 0 1 (20) 3 (30) 3 (30)
Increased amylase 0 1 (20) 3 (30) 2 (20) 2 (40) 0 0 3 (30)
Hypotension 0 1 (20) 2 (20) 3 (30) 0 0 2 (20) 2 (20)
Pain 0 2 (40) 3 (30) 1 (10) 0 0 1 (10) 1 (10)
Dizziness 1 (20) 1 (20) 3 (30) 0 0 0 1 (10) 1 (10)
Abnormal liver function tests 0 1 (20) 1 (10) 4 (40) 0 1 (20) 0 1 (10)
Infection 0 0 0 0 1 (20) 0 3 (30) 0
Diarrhea 0 2 (40) 0 0 1 (20) 0 1 (10) 0
Impaired urination 0 0 0 0 2 (40) 0 0 0
Hb, Hemoglobin.
Data are number of patients (%).
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The mean lipase level for hemoglobin raffimer–treated pa-
tients was 403 U/L (upper limit of normal, 190 U/L), with
a peak at 24 hours after surgery, and it returned to normal
levels by 48 to 72 hours. The mean lipase level for pen-
tastarch-treated patients did not exceed the reference range.
In addition, there was an increase in mean amylase levels in
20 (67%) hemoglobin raffimer–treated patients, with a peak
mean amylase level of 293  196 U/L at 24 hours, whereas
26 (86%) controls had increased amylase levels, with a peak
mean of 304  149 U/L at 24 hours. Amylase levels
returned to the reference range (upper limit of normal, 220
U/L) by 48 to 72 hours after surgery. None of the observed
increases in serum amylase or lipase levels were accompa-
nied by clinical signs or symptoms of pancreatitis.
After infusion of hemoglobin raffimer, total bilirubin
levels demonstrated an expected dose-related increase
within 24 hours after surgery. Bilirubin levels began to
decline by 48 hours and returned to baseline by 72 hours
after surgery. Mean total bilirubin values at 24 hours ranged
from 21.1 mol/L in the 250-mL hemoglobin raffimer
group to 46.7 mol/L in the 1000-mL hemoglobin raffimer
group. Liver enzymes (alkaline phosphatase, alanine ami-
notransferase, aspartate aminotransferase, and -glutamyl-
transferase) were similar across all dose groups and both
treatment groups. Systemic oxygenation was assessed in
both arterial and mixed venous blood. Oxygenation param-
eters for combined dose blocks at the 45-minute time point
during CPB and in the ICU are shown in Table 5. Oxygen
delivery rates and measurements of oxygenation variables
in mixed venous blood were consistently higher in hemo-
globin raffimer–treated patients than in pentastarch-treated
patients during CPB but were not statistically different.
Oxygenation parameters in arterial blood demonstrated no
statistically significant difference between treatment groups.
After CPB, these variables were similar in both treatment
groups. Oxygen consumption rates and oxygen extraction
rates were similar in hemoglobin raffimer–treated and pen-
tastarch-treated patients, both during CPB and in the ICU.
Patients were also tested for immunoreactivity to hemo-
globin raffimer. Pretreatment samples were obtained for 27
pentastarch-treated and 29 hemoglobin raffimer–treated pa-
tients. Posttreatment samples were collected at the fol-
low-up 4- to 6-week postsurgery visit for 22 pentastarch-
treated and 23 hemoglobin raffimer–treated patients. In
these subsets, no patient exhibited immunoreactivity toward
hemoglobin raffimer before study treatment, and 4 (17%)
hemoglobin raffimer–treated patients (3 receiving 500 mL
and 1 receiving 1000 mL of hemoglobin raffimer) showed
immunoreactivity after study treatment. Skin rash (n  4)
and pruritus (n  1) were reported in hemoglobin raffimer–
treated patients during the study. However, only 1 episode
of rash, which occurred in a patient who received 500 mL of
hemoglobin raffimer and who tested positive for anti–he-
moglobin raffimer antibody, was considered possibly re-
lated to study medication.
Discussion
Because of the risks associated with allogeneic blood trans-
fusion, there has been increasing interest in the clinical
development of oxygen delivery systems to facilitate blood
conservation. This study examined the efficacy, adverse
events, and biochemical profile of escalating doses (250 to
1000 mL) of hemoglobin raffimer in patients undergoing
CABG. In this study, increased blood pressure, atrial fibril-
lation, and jaundice were the most frequently reported ad-
verse events in hemoglobin raffimer–treated patients.
In general, the adverse events reported in this study were
similar to events commonly reported in the literature for
CABG patients.10,11 The most frequently reported cardio-
vascular adverse event, atrial fibrillation, occurred more
frequently in hemoglobin raffimer–treated than in pen-
tastarch-treated patients (37% vs 17%, respectively). How-
ever, the incidence of atrial fibrillation in hemoglobin raf-
fimer–treated patients was within the range of 20% to 40%
reported for CABG patients,12-15 and most of these episodes
occurred more than 48 hours after hemoglobin raffimer
administration, by which time most (approximately 75%) of
the hemoglobin raffimer had cleared the patients’ systems.
Hypertension is a recognized complication in CABG
and, depending on their preoperative state, may occur in
30% to 80% of patients.16 Previous studies have shown that
hemoglobin-based oxygen carriers may cause vasoconstric-
TABLE 4. Pooled adverse events reported by treatment
group
Adverse event
Hb raffimer
(n  30)
Pentastarch
(n  30)
P
value*
Hypertension 13 (43) 5 (17) .047
Nausea 11 (37) 10 (33) .79
Atrial fibrillation 11 (37) 5 (17) .14
Jaundice 11 (37) 0 .0008
Myocardial infarction 6 (20) 8 (27) .76
Fever 6 (20) 7 (23) .75
Increased amylase 6 (20) 5 (17) .74
Hypotension 6 (20) 4 (13) .73
Pain 6 (20) 2 (7) .25
Dizziness 5 (17) 2 (7) .42
Vomiting 5 (17) 2 (7) .42
Abnormal liver function tests 5 (17) 2 (7) .42
Hemorrhage 4 (13) 3 (10) .69
Dyspnea 1 (3) 4 (13) .35
Rash 4 (13) 0 .12
Infection 0 4 (13) .12
Increased cough 3 (10) 0 .24
Myocardial ischemia 3 (10) 0 .24
Hb, Hemoglobin.
Data are number of patients (%).
*Two-tailed Fisher exact test.
Cardiopulmonary Support and Physiology Cheng et al
84 The Journal of Thoracic and Cardiovascular Surgery ● January 2004
CSP
tion and increase mean arterial pressure in a dose-dependent
manner.17-20 This hemodynamic effect seems to be related
to nitric oxide scavenging by the hemoglobin molecule and
to the release of endothelin-1,21-24 but other (eg, adrenergic)
mechanisms may also be involved.25 Therefore, an increase
in blood pressure, reported more frequently in the hemo-
globin raffimer–treated patients, was not unexpected in this
study. A nonsignificant increase in blood pressure in hemo-
globin raffimer–treated patients relative to pentastarch-
treated patients was approximately 5% to 8% (5 to 10 mm
Hg) during the first 24 hours after administration, although
there was high variability between the 2 groups. A phase I
study reported an approximately 15% increase in mean
arterial pressure in normotensive volunteers who received
hemoglobin raffimer.9 A concomitant reduction in heart
rate, with no associated ECG abnormalities, was also noted
in this phase I study. In the current study, investigators were
aware that hypertension could occur in the treated groups.
Therefore, the reduction in the percentage increase in blood
pressure between the hemoglobin raffimer and pentastarch
groups was likely the result of more aggressive administra-
tion of -blockers, calcium channel blockers, or both by the
investigators. -Blockers were used in 23 (77%) of the
hemoglobin raffimer–treated patients compared with 2 (7%)
of the pentastarch-treated patients. It seems that hyperten-
sion associated with the use of hemoglobin raffimer is
common but can be readily managed with conventional
antihypertensive medications.
A dose-dependent increase in bilirubin in patients who
received hemoglobin raffimer was also expected in this
study because the metabolism of cell-free hemoglobin prod-
ucts26 is known to cause an increase in bilirubin, a normal
product of heme catabolism. The incidence of jaundice was
consistent with the dose-dependent increase in total biliru-
bin reported in the hemoglobin raffimer group. However,
the observed increase in total bilirubin was considered mild
and was adequately and safely cleared by the liver.
The incidence of MI observed in this study was within
the range (2% to 26%) reported perioperatively in CABG
patients whose MI was diagnosed by both ECG and creatine
kinase/myocardial muscle subtraction criteria,27-29 but it
was not different between study groups. This is noteworthy
in light of the more inclusive criteria used to define an MI
in this study (eg, a broader range of ECG changes and a
lower threshold of serum creatine kinase/myocardial muscle
subtraction levels). The fact that this study was designed to
address the dose-response of hemoglobin raffimer may have
biased the pooled data against efficacy because the smaller
doses are unlikely to result in significant blood conserva-
tion. Systemic oxygenation was well maintained in hemo-
globin raffimer–treated patients.
This study demonstrated that administration of hemoglo-
bin raffimer reduced the rate of allogeneic RBC transfusion
when used in conjunction with IAD in patients undergoing
primary CABG surgery. The mean total hemoglobin con-
centration was approximately 2 g/dL higher in the hemo-
globin raffimer group than in the control group after the
IAD procedure, which may have helped to avoid transfu-
sions in the hemoglobin raffimer group. In patients who
required allogeneic RBC transfusions, hemoglobin raf-
fimer–treated patients received a smaller volume (ie, fewer
units) than pentastarch-treated patients, even though the
harvested volume of acute normovolemic hemodilution
blood was comparable in the 2 groups. The difference in
allogeneic blood volume received was not statistically sig-
nificant, perhaps because of the large variation observed in
the pentastarch group. A larger sample size will be required
to definitively determine whether hemoglobin raffimer leads
to a statistically significant reduction in allogeneic blood
volume.
This phase II study demonstrated that hemoglobin raf-
fimer up to 1000 mL was not associated with any serious
adverse events in patients undergoing CABG surgery with
CPB. In addition, the study suggested that hemoglobin
TABLE 5. Mean oxygenation parameters during and after CPB
Parameter
During 45 min of CPB After CPB
Hb raffimer Pentastarch P value Hb raffimer Pentastarch P value
V˙O2 (mL · min
1 · m2) 111.5 53.8 109.6 53.4 .89 167.0 51.3 161.9 41.4 .67
DO2 (mL · min
1 · m2) 464.7 181.8 368.6 139.9 .03 643.7 153.2 679.9 239.5 .49
Pump flow rate or cardiac
index (L · min1 · m2)
3.7 1.4 3.6 1.3 .78 2.5 0.6 3.2 1.0 .0017
Total Hb (g/L) 85.5 11.0 69.5 8.6 .0001 91.1 18.1 77.5 9.7 .0006
Mixed venous oxygen
saturation (%)
77.2 8.2 73.3 7.2 .055 78.2 7.0 79.7 7.0 .41
Mixed venous PO2 (mm Hg) 47.6 13.7 40.8 7.8 .023 45.2 6.0 46.6 6.7 .40
Oxygen extraction ratio 0.26 0.07 0.30 0.08 .044 0.26 0.07 0.25 0.07 .58
Data are mean  SD; t test.
CPB, Cardiopulmonary bypass; Hb, hemoglobin; V|ApO2, oxygen consumption; DO2, oxygen delivery; PO2, partial pressure of oxygen.
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raffimer may be an effective oxygen-therapeutic adjunct to
other blood-conservation strategies used in CABG surgery
to reduce, delay, or avoid allogeneic RBC transfusions.
Studies to further characterize the safety and efficacy profile
of hemoglobin raffimer as an oxygen-therapeutic adjunct in
CABG surgery are warranted.
Statistical analysis was conducted by Nancy Wang, PhD (Mac-
Dougal Scientific).
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